Clinical Trials · NCT04216589
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Enrollment
- 51
- Start date
- Feb 2021
- Locations
- 9 sites, United States, Brazil
- Primary endpoint
- Change (Absolute) in IHTG (%)